Accordingly, we demonstrate that TRABID overexpression enables synthetic lethality to PARP inhibition in prostate cancer, stressing that TRABID overexpression represents a vulnerability to PARP inhibitors in cancers such as prostate cancer. Here, ZRANB1 is linked to Familial prostate cancer.